R&D | April 15, 2026
Regeneron and Telix strike major radiopharma pact in push into next-gen cancer therapies
The companies plan to advance multiple solid tumor targets from Regeneron’s antibody portfolio
The companies plan to advance multiple solid tumor targets from Regeneron’s antibody portfolio
Funding to accelerate growth of concierge-style private health services and Aayu’s paperless hospital infrastructure platform
A major push to sharpen the future of cancer treatment is underway
The partnership aims to fuse antibody-drug conjugation (ADC) technology with targeted protein degradation
Hyderabad-based peptide specialist strengthens complex generics credentials as Apotex prepares for U.S. commercialization of semaglutide injection
The study is a global, randomized, double-blind, placebo-controlled trial testing GLM101 for phosphomannomutase 2 congenital disorder of glycosylation
Final approval for progesterone vaginal inserts expands Glenmark’s women’s healthcare portfolio in the US, targeting a market of over $59 million
In just the last few days, companies including Lupin, Biocon, Alembic Pharmaceuticals and Aurobindo Pharma have announced approvals for 5 mg and 10 mg tablets, all bioequivalent to Farxiga
TG4050 harnesses Transgene’s myvac platform and NEC’s AI-powered neoantigen prediction technology to tailor vaccines to each patient’s tumor
TriNetX will provide Regeneron secure, licensed access to de-identified health data from its global network of health system partners
Subscribe To Our Newsletter & Stay Updated
